Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Total Debt (2016 - 2025)

Rhythm Pharmaceuticals (RYTM) has disclosed Total Debt for 5 consecutive years, with $108.2 million as the latest value for Q4 2025.

  • Quarterly Total Debt fell 1.47% to $108.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $108.2 million through Dec 2025, down 1.47% year-over-year, with the annual reading at $108.2 million for FY2025, 1.47% down from the prior year.
  • Total Debt for Q4 2025 was $108.2 million at Rhythm Pharmaceuticals, down from $109.0 million in the prior quarter.
  • The five-year high for Total Debt was $109.8 million in Q4 2024, with the low at $106.1 million in Q4 2023.
  • Average Total Debt over 3 years is $108.7 million, with a median of $109.2 million recorded in 2025.
  • The sharpest move saw Total Debt grew 3.45% in 2024, then dropped 1.47% in 2025.
  • Over 3 years, Total Debt stood at $106.1 million in 2023, then increased by 3.45% to $109.8 million in 2024, then dropped by 1.47% to $108.2 million in 2025.
  • According to Business Quant data, Total Debt over the past three periods came in at $108.2 million, $109.0 million, and $109.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.